IDEXX LABORATORIES INC /DE Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | $1.1B | — | $274.6M | — | $354.8M | $3.40 |
| Q2 FY202510-Q · 2025-06-30 | $46.7M | — | -$131.0K | — | $1.0M | $3.63 |
| Q1 FY202510-Q · 2025-03-31 | $344.8M | — | $242.7M | — | $1.1M | $2.96 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $3.4B | $1.8B | $208.2M | $1.6B |
| Q2 FY202510-Q | $3.3B | $1.9B | $164.6M | $5.9B |
| Q1 FY202510-Q | $3.2B | $1.8B | $164.0M | -$90.1M |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | $354.8M | $274.6M | $683.4M | 79,999,000 |
| Q2 FY202510-Q | $1.0M | -$131.0K | $692.5M | 80,150,000 |
| Q1 FY202510-Q | $1.1M | $242.7M | $32.1M | 80,740,000 |
Filings
(4)Methodology
Every figure on this page is pulled directly from IDEXX LABORATORIES INC /DE's own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].